Oncternal Therapeutics, Inc. Gains 88.08%

Fri, May 27, 2022 at 05:30 PM

Oncternal Therapeutics, Inc. (ONCT:NASDAQ) jumped higher at $1.54, representing a gain of 88.1%. The stock appeared on our News Catalysts scanner on Thu, May 26, 2022 at 05:49 PM in the 'MERGER' category. From Fri, May 13, 2022, the stock recorded 44.44% Up Days and 50.00% Green Days

About Oncternal Therapeutics, Inc. (ONCT:NASDAQ)

GTx Inc is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of small molecules for the treatment of cancer including treatment of breast and prostate cancer and other serious medical conditions such as Stress urinary incontinence and Duchenne muscular dystrophy. Its lead product candidate is Enobosarm. The company's strategy is focused on the further development of selective androgen receptor modulators.

Top 10 Gainers:

Avadel Pharmaceuticals plc (AVDL:NASDAQ), 133.64%
Oncternal Therapeutics, Inc. (ONCT:NASDAQ), 88.08%
Allarity Therapeutics Inc. (ALLR:NASDAQ), 39.32%
Imperial Petroleum Inc. (IMPP:NASDAQ), 38.38%
JE Cleantech Holdings Limited (JCSE:NASDAQ), 34.8%
Merus N.V. (MRUS:NASDAQ), 32.55%
Farfetch Limited (FTCH:NYSE), 26.69%
Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ), 25.71%
Grom Social Enterprises Inc. (GROM:NASDAQ), 25.48%
Icosavax Inc. (ICVX:NASDAQ), 25.37%